Loading clinical trials...
Loading clinical trials...
An Open-Label Dose Escalation Trial to Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD), Safety, and Tolerability of Microneedle Arrays Containing Doxorubicin (D-MNA) in Participants With Basal Cell Carcinoma (BCC)
Conditions
Interventions
Placebo-containing MNA
25 µg doxorubicin-containing MNA
+3 more
Locations
1
United States
The Center for Clinical and Cosmetic Research
Aventura, Florida, United States
Start Date
June 10, 2020
Primary Completion Date
March 1, 2021
Completion Date
May 4, 2021
Last Updated
March 12, 2024
NCT07144384
NCT03050268
NCT07182240
NCT06623201
NCT05020912
NCT07010692
Lead Sponsor
SkinJect, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions